NCAC I and II (Addiction Counselor)

Central nervous system depressants slow brain activity, producing sedation, decreased anxiety, muscle relaxation, and at higher doses, respiratory depression and unconsciousness. Major classes include alcohol, benzodiazepines, barbiturates, and opioids.

Alcohol (ethanol) is the most commonly used psychoactive substance worldwide. Alcohol enhances gamma-aminobutyric acid (GABA) activity at GABA-A receptors, producing inhibitory effects. Alcohol also inhibits glutamate activity at N-methyl-D-aspartate (NMDA) receptors, further reducing excitatory neurotransmission. Chronic alcohol exposure produces compensatory upregulation of excitatory systems, contributing to withdrawal severity.

Alcohol intoxication progresses through stages correlating with blood alcohol concentration. Low concentrations produce disinhibition, impaired judgment, and mild coordination problems. Moderate concentrations cause slurred speech, significant motor impairment, and emotional lability. High concentrations produce severe intoxication with potential for respiratory depression, aspiration, and death.

Alcohol withdrawal ranges from mild tremulousness to life-threatening delirium tremens. Withdrawal symptoms typically begin six to twelve hours after last drink, peak at 24-72 hours, and resolve within five to seven days. Minor withdrawal includes tremor, anxiety, insomnia, and gastrointestinal distress. Severe withdrawal may include seizures, hallucinations, and delirium tremens characterized by confusion, autonomic hyperactivity, and potential cardiovascular collapse.

Benzodiazepines are prescribed for anxiety, insomnia, seizures, and muscle relaxation. They enhance GABA activity at a specific benzodiazepine binding site on the GABA-A receptor. Common benzodiazepines include diazepam, alprazolam, lorazepam, and clonazepam. Benzodiazepines are classified by duration of action: short-acting (triazolam), intermediate-acting (alprazolam, lorazepam), and long-acting (diazepam, clonazepam).

Benzodiazepine dependence develops with chronic use, producing tolerance and withdrawal upon discontinuation. Withdrawal symptoms include rebound anxiety, insomnia, tremor, and potentially seizures. Benzodiazepine withdrawal requires gradual tapering to prevent complications.

Opioids include natural derivatives of the opium poppy (morphine, codeine), semi-synthetic compounds (heroin, oxycodone, hydrocodone), and fully synthetic substances (fentanyl, methadone). Opioids bind to mu, kappa, and delta opioid receptors throughout the central nervous system and peripheral tissues. Mu receptor activation produces analgesia, euphoria, respiratory depression, and constipation.

Opioid intoxication causes miosis (pinpoint pupils), respiratory depression, decreased consciousness, and constipation. Overdose risk is highest with respiratory depression, which can be fatal. Naloxone is an opioid antagonist that rapidly reverses overdose by displacing opioids from receptors.

Opioid withdrawal, while intensely uncomfortable, is rarely life-threatening in healthy adults. Symptoms include dysphoria, anxiety, muscle aches, lacrimation, rhinorrhea, piloerection, yawning, fever, insomnia, nausea, vomiting, and diarrhea. Withdrawal typically begins eight to twelve hours after last short-acting opioid use, peaks at 36-72 hours, and resolves within seven to ten days. Long-acting opioids produce delayed but prolonged withdrawal.

Barbiturates are sedative-hypnotic drugs derived from barbituric acid. Once widely prescribed for anxiety and insomnia, barbiturate use has declined due to narrow therapeutic index, high abuse potential, and severe withdrawal syndrome. Barbiturates remain used medically for seizure control (phenobarbital) and anesthesia induction (thiopental).

Barbiturates enhance GABA activity at GABA-A receptors through a mechanism distinct from benzodiazepines. At high concentrations, barbiturates directly activate GABA receptors independent of GABA binding. This property contributes to their greater toxicity compared to benzodiazepines.

Barbiturates are classified by duration of action: ultra-short-acting (thiopental, methohexital) used for anesthesia, short-acting (secobarbital, pentobarbital) historically used as sleeping pills, intermediate-acting (amobarbital, butabarbital), and long-acting (phenobarbital) used for seizure control.

Barbiturate intoxication resembles alcohol intoxication, with slurred speech, incoordination, impaired judgment, and mood lability. Higher doses produce respiratory depression, coma, and death. The margin between therapeutic and lethal doses is narrow, making overdose common.

Barbiturate withdrawal is medically serious and potentially fatal. Symptoms begin 12-20 hours after last dose and include anxiety, tremor, weakness, nausea, vomiting, and orthostatic hypotension. Severe withdrawal may include seizures, delirium, and cardiovascular collapse. Medical detoxification with gradual dose reduction or cross-substitution with long-acting barbiturates or benzodiazepines is essential.

Tolerance to barbiturates develops rapidly, requiring escalating doses to achieve desired effects. Cross-tolerance exists between barbiturates, benzodiazepines, and alcohol, allowing substitution during withdrawal management.